CN102526461A - Application of traditional Chinese medicine composition in preparing medicament for resisting myocardial cell hypoxic injury - Google Patents
Application of traditional Chinese medicine composition in preparing medicament for resisting myocardial cell hypoxic injury Download PDFInfo
- Publication number
- CN102526461A CN102526461A CN2010105815388A CN201010581538A CN102526461A CN 102526461 A CN102526461 A CN 102526461A CN 2010105815388 A CN2010105815388 A CN 2010105815388A CN 201010581538 A CN201010581538 A CN 201010581538A CN 102526461 A CN102526461 A CN 102526461A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- medicine composition
- carapax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a traditional Chinese medicine composition in preparing a medicament for resisting myocardial cell hypoxic injury. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in proportion by weight: 1-10 parts of rehmannia root, 1-10 parts of spatholobus stem, 1-7 parts of ophiopogon root, 1-7 parts of liquorice, 1-7 parts of prepared fleece-flower root, 1-7 parts of donkey-hide gelatin, 1-7 parts of magnolia vine fruit, 1-7 parts of dangshen, 1-5 parts of tortoise shell, 1-5 parts of jujube and 0.1-2 parts of cassia twig. The invention also discloses a preparation method of the traditional Chinese medicine composition.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to the application of a kind of Chinese medicine composition in preparation anti-myocardial anoxia-induced apoptosis medicine.
Background technology
Myocardial ischemia belongs to the category of the traditional Chinese medical science thoracic obstruction, and " Chinese Internal Medicine " is divided into six kinds of pattern of syndrome with the thoracic obstruction, is respectively that stagnation of heart-blood, expectorant turbidly are jammed, YIN-cold stagnates, heart deficiency of the kidney yin, deficiency of both QI and YIN and deficient and weak YANG QI.
TONGMAIYANXINWAN is a kind of Chinese patent medicine of treating ischemic heart desease, is formed by SHENGMAI SAN and zhigancao decoction plus-minus, and having nourishes heart enriches blood, the effect of coronary circulation-promoting pain-relieving.The clinical cards such as treatment obstruction of qi in the chest and cardialgia, severe palpitation that are mainly used in.Clinical trial confirms that freeing vessels and nourishing heart pill for curing coronary artery disease with deficiency of both qi and yin is evident in efficacy, but its pharmacological mechanism is still indeterminate.The long-time anoxia of research confirmed myocardial cell can cause myocardial tissue damage and necrosis; Impaired myocardial cell inflammatory factor overexpression; Wherein but IL-1 β irritation cell produces the irritability oxygen molecule, and the myocardial cell membrane permeability is increased, and produces MDA and makes the ATP biosynthesis block; Thereby directly damage the electrophysiological function and the blood-pumping function of heart, finally make myocardial cell degeneration, necrosis.Therefore this paper will inquire into its possible mechanism of action from two aspects of expression of oxidative stress and inflammatory factor.
Summary of the invention
The object of the invention is to provide the application of a kind of Chinese medicine composition in preparation anti-myocardial anoxia-induced apoptosis medicine.
Another purpose of the present invention is to provide the application of a kind of Chinese medicine composition in the cardiotropic formulation that preparation treatment myocardial cell anoxia causes.The heart disease that said myocardial cell anoxia causes includes, but are not limited to coronary heart disease, and angina pectoris and other are because the heart disease that the myocardial cell anoxia causes.
Chinese medicine composition of the present invention is prepared from according to the Chinese medicine of following weight proportioning:
1～10 part of Radix Rehmanniae, 1～10 part of Caulis Spatholobi, 1～7 part of Radix Ophiopogonis, 1～7 part in Radix Glycyrrhizae, 1～7 part of Radix Polygoni Multiflori Preparata, 1～7 part in Colla Corii Asini, 1～7 part of Fructus Schisandrae Chinensis, 1～7 part of Radix Codonopsis, 1～5 part of Carapax Et Plastrum Testudinis, 1～5 part in Fructus Jujubae, 0.1～2 part of Ramulus Cinnamomi.
Preferably, Chinese medicine composition of the present invention is prepared from according to the Chinese medicine of following weight proportioning:
3～8 parts of Radix Rehmanniae, 3～8 parts of Caulis Spatholobis, 2～5 parts of Radix Ophiopogonis, 2～5 parts in Radix Glycyrrhizae, 2～5 parts of Radix Polygoni Multiflori Preparatas, 2～5 parts in Colla Corii Asini, 2～5 parts of Fructus Schisandrae Chinensis, 2～5 parts of Radix Codonopsis, 1～3 part of Carapax Et Plastrum Testudinis, 1～3 part in Fructus Jujubae, 0.5～1.5 part of Ramulus Cinnamomi.
Most preferably, Chinese medicine composition of the present invention is prepared from according to the Chinese medicine of following weight proportioning:
5 parts of Radix Rehmanniae, 5 parts of Caulis Spatholobis, 3 parts of Radix Ophiopogonis, 3 parts in Radix Glycyrrhizae, 3 parts of Radix Polygoni Multiflori Preparatas, 3 parts in Colla Corii Asini, 3 parts of Fructus Schisandrae Chinensis, 3 parts of Radix Codonopsis, 2 parts of Carapax Et Plastrum Testudiniss, 2 parts in Fructus Jujubae, 1 part of Ramulus Cinnamomi.
Wherein, in order to reach better therapeutic effect, described Carapax Et Plastrum Testudinis is a Carapax et Plastrum Testudinis(processed with vinegar).
Therefore, Chinese medicine composition of the present invention is prepared from according to the Chinese medicine of following weight proportioning:
1～10 part of Radix Rehmanniae, 1～10 part of Caulis Spatholobi, 1～7 part of Radix Ophiopogonis, 1～7 part in Radix Glycyrrhizae, 1～7 part of Radix Polygoni Multiflori Preparata, 1～7 part in Colla Corii Asini, 1～7 part of Fructus Schisandrae Chinensis, 1～7 part of Radix Codonopsis, 1～5 part of Carapax Et Plastrum Testudinis (vinegar system), 1～5 part in Fructus Jujubae, 0.1～2 part of Ramulus Cinnamomi.
Preferably, Chinese medicine composition of the present invention is prepared from according to the Chinese medicine of following weight proportioning:
3～8 parts of Radix Rehmanniae, 3～8 parts of Caulis Spatholobis, 2～5 parts of Radix Ophiopogonis, 2～5 parts in Radix Glycyrrhizae, 2～5 parts of Radix Polygoni Multiflori Preparatas, 2～5 parts in Colla Corii Asini, 2～5 parts of Fructus Schisandrae Chinensis, 2～5 parts of Radix Codonopsis, 1～3 part of Carapax Et Plastrum Testudinis (vinegar system), 1～3 part in Fructus Jujubae, 0.5～1.5 part of Ramulus Cinnamomi.
Most preferably, Chinese medicine composition of the present invention is prepared from according to the Chinese medicine of following weight proportioning:
5 parts of Radix Rehmanniae, 5 parts of Caulis Spatholobis, 3 parts of Radix Ophiopogonis, 3 parts in Radix Glycyrrhizae, 3 parts of Radix Polygoni Multiflori Preparatas, 3 parts in Colla Corii Asini, 3 parts of Fructus Schisandrae Chinensis, 3 parts of Radix Codonopsis, 2 parts of Carapax Et Plastrum Testudiniss (vinegar system), 2 parts in Fructus Jujubae, 1 part of Ramulus Cinnamomi.
Aforementioned Chinese medicine composition can be according to the method processing of arbitrary routine in the prior art, and the extract that obtains all has the effect of anti-myocardial anoxia-induced apoptosis.For the ease of understanding, be exemplified below at present, but do not constitute influence for protection domain of the present invention.
Method one, Chinese medicine composition of the present invention are prepared from according to following method, comprising:
Step 1, according to above-mentioned weight proportion get 11 the flavor medical materials;
Step 2, get the Carapax Et Plastrum Testudinis decocte with water after, add Caulis Spatholobi, Radix Codonopsis, Fructus Jujubae and continue to decoct, filter, after filtrating concentrates; Add ethanol and precipitate, get an amount of supernatant, add the Colla Corii Asini post-heating and make dissolving, incorporate in the above-mentioned alcoholic solution; Mixing leaves standstill, and filters filtrate for later use;
Step 3, all the other 6 flavor medical materials, after the adding alcohol dipping, percolation is collected the extracting solution that obtains in percolate and the step 2 and is merged, and leaves standstill, and filters, and decompression filtrate recycling ethanol obtains finished product.
Wherein, in step 2, said Carapax Et Plastrum Testudinis decocte with water adds medical materials such as Caulis Spatholobi after 2 hours; Add medical material continued such as Caulis Spatholobi, Radix Codonopsis and Fructus Jujubae and decoct 2 times, 4 hours for the first time, 2 hours for the second time; It is 1.05～1.15 (50 ℃) that said filtrating is concentrated into relative density; Add 80% ethanol and precipitate, make ethanol content reach 60%; Get an amount of supernatant (exceeding) can dissolve the Colla Corii Asini medical material fully; Left standstill 24 hours.
In the step 3, the alcohol dipping of employing 80% 48 hours; Left standstill 24 hours.
Preferably, Chinese medicine composition of the present invention is prepared from according to following method: comprise
Step 1, according to above-mentioned weight proportion get 11 the flavor medical materials;
Step 2, get the Carapax Et Plastrum Testudinis decocte with water after 2 hours, add Caulis Spatholobi, Radix Codonopsis, Fructus Jujubae and continue to decoct 2 times, 4 hours for the first time, 2 hours for the second time; Filter, after filtrating is concentrated into relative density and is 1.05～1.15 (50 ℃), add 80% ethanol and precipitate to make and contain the alcohol amount and reach 60%, get an amount of supernatant; Add the Colla Corii Asini post-heating and make dissolving, incorporate in the above-mentioned alcoholic solution mixing into; Left standstill 24 hours, and filtered filtrate for later use;
Step 3, all the other 6 flavor medical materials added 80% alcohol dipping after 48 hours, and percolation is collected the extracting solution that obtains in percolate and the step 2 and merged, and leaves standstill 24 hours, filters, and decompression filtrate recycling ethanol obtains finished product.
Method two, Chinese medicine composition of the present invention are prepared from according to following method, comprising:
Step 1, according to above-mentioned weight proportion get 11 the flavor medical materials;
Step 2, Caulis Spatholobi, Radix Codonopsis, Fructus Schisandrae Chinensis, Fructus Jujubae, Carapax Et Plastrum Testudinis decocte with water, merging filtrate filters, and is condensed into thick paste;
Step 3, all the other medical material 6 flavor medicine branches are broken into fine powder, add the thick paste that step 1 obtains, and evenly, drying divides to be broken into fine powder, obtains finished product.
Wherein, in the step 2, medical material decocts 2 times, each 3 hours.
Preferably, Chinese medicine composition of the present invention is prepared from according to following method: comprise
Step 1, according to above-mentioned weight proportion get 11 the flavor medical materials;
Step 2, Caulis Spatholobi, Radix Codonopsis, Fructus Schisandrae Chinensis, Fructus Jujubae, Carapax Et Plastrum Testudinis decocte with water 2 times, each 3 hours, merging filtrate filtered, and is condensed into thick paste;
Step 3, all the other medical material 6 flavor medicine branches are broken into fine powder, add the thick paste that step 1 obtains, and evenly, drying divides to be broken into fine powder, obtains finished product.
Pharmaceutical composition of the present invention is reused the Radix Rehmanniae nourishing YIN and benefiting blood to the pathological state of thoracic obstruction deficiency in origin and excess in superficiality and is monarch, " Mingyi Bielu " meaning Radix Rehmanniae " the tonifying five ZANG-organs internal injury is not enough, promoting blood circulation, physical strength profiting ".Radix Glycyrrhizae Preparata, Radix Codonopsis, Fructus Jujubae QI invigorating in the side, spleen invigorating; Radix Rehmanniae, Colla Corii Asini, Radix Ophiopogonis sweet profit nourishing heart yin painstaking effort; Ramulus Cinnamomi, Caulis Spatholobi temperature promoting blood circulation match with the supplementing QI and nourishing YIN medicine, also can make qi and blood circulation, the sering tonneau.All medicines are harmonious and can reach cloudy hemapodium and blood vessels fill, the multiple and heart beniol of yang-energy, and QI and blood is abundant, and blood vessels are unimpeded then throbs with fear and can decide, and arteries and veins can be answered.Modern pharmacology research confirms that ground yellow fluid extract has effects such as blood pressure lowering, antiinflammatory; Its extractum has effects such as heart tonifying, diuresis.Radix Codonopsis has antioxidation.Radix Ophiopogonis, Ramulus Cinnamomi have the effect that improves myocardial contraction.Caulis Spatholobi has pharmacological actions such as atherosclerosis.The modern pharmacology experiment shows that pharmaceutical composition of the present invention possibly pass through antiinflammatory, antioxidation performance myocardium protecting action.
Test Example is to the influence of hypoxia inducible myocardial cell inflammatory factor and oxidative stress
Below its possible mechanism of action is inquired into from two aspects of expression of oxidative stress and inflammatory factor for pharmaceutical composition of the present invention.
1 materials and methods
1.1 animal
50 of Wistar rats, body weight 300 ± 20g, male, purchase consonance zooscopy institute, quality certification numbering: SCXK (capital) 2005-0013 in the Chinese Academy of Medical Sciences.Raise the Experimental Animal Center in Tianjin University Of Traditional Chinese Medicine, environmental facility meets " Ministry of Health of the People's Republic of China's laboratory animal environmental facility standard " secondary standard.
Newborn 1-3d Wistar rat, male and female are regardless of, and purchase in radiological study institute of consonance medical university of the Chinese Academy of Medical Sciences.
1.2 main medicine and reagent
Pharmaceutical composition of the present invention (call " TONGMAIYANXINWAN " in the following text, Lerentang Pharmaceutical Factory, Zhongxin Pharmaceutical Group Co., Ltd., Tianj provides, according to the method preparation of the embodiment of the invention 1, and the heavy 1g of per 10 balls, lot number: C107074); DMEM/F12 culture fluid (Hyclone); Trypsin 1: 250, sigma); II Collagen Type VI enzyme (Gibco company); 5-bromouracil deoxyribose (brdu, sigma company); SOD, MDA, GSH detection kit (bio-engineering research institute is built up in Nanjing); Rat IL-1 β, IL-6 test kit (R&D); Other reagent are homemade analytical pure.
1.3 key instrument
37 ℃ of 5%CO
2Incubator (THERMO, FORMA3111 type, the U.S.); 37 ℃ of 94%N
2-5%CO
2-1%O
2Incubator (THERMO, FORMA3131 type, the U.S.); Inverted phase contrast microscope (LEICA DMIL, Germany); Desk type high speed refrigerated centrifuge (Biofuge primo R, the U.S.); ELIASA (Multiskan Ascent, THERMO LABSYSTEMS, the U.S.); 300 type semi-automatic biochemical analyzers (Dutch prestige figure).
1.4 experimental technique
1.4.1 the preparation of pastille serum
50 Wistar rats are divided into blank group, TONGMAIYANXINWAN 1g/kg, 2g/kg, 4g/kg, 8g/kg (day dosage) dose groups at random; Every group 10, the blank group is irritated clothes equivalent distilled water, the administration group face with preceding with distilled water be mixed with 0.05,0.1,0.2, the 0.4g/ml medicinal liquid; Supply rat oral gavage; The administration volume is that 1ml/100g irritates clothes administration, every day twice, successive administration three days.Behind the last administration 1h, abdominal aortic blood is got serum behind the centrifugal 15min of 3000rpm, hatches 30min deactivation complement in 56 ℃ of water baths, and aseptic condition filters down and divides in the frozen pipe of packing into, and-20 ℃ of refrigerators are preserved subsequent use.
1.4.2 In vitro culture myocardial cell anoxia-induced apoptosis Preparation of model
1.4.2.1 myocardial cell is former be commissioned to train foster
The reference literature method improves carry out myocardial cell former and is commissioned to train foster: aseptic condition takes out ventricular organization down; Digest 4-5 time with 37 ℃ of 0.1% warm in advance collagenases and 1: 1 mixed liquor of 0.06% trypsin, each 5min gets the Digestive system supernatant and partly filters 200 order mesh screens; Centrifugal collection is each time digestion gained cell except that for the first time; Be suspended from the DMEM/F12 culture fluid that contains 10% hyclone and (include 100 μ g/ml penicillins, 100 μ g/ml streptomycins), be inoculated in 75cm
2In the culture bottle, collect not adherent myocardial cell behind the differential adhere-wall culture 1h and be suspended from again in the DMEM/F12 culture fluid that contains 10% hyclone, adjustment cell concentration to 3 * 10
5～5 * 10
5/ ml is inoculated in 96 orifice plates, and every hole 100 μ l change liquid every other day, adds with 0.1mmol/LBrdu to suppress non-myocardial cell growth in preceding 3 days.
1.4.2.2 group technology
Got the monolayer myocardial cell of culture successful on the 4th day, cultivate 48h, make cell growth synchronization with serum-free DMEM/F12 culture fluid.Experiment divides 6 groups: (1) blank group (2) anoxia-induced apoptosis group (3) TONGMAIYANXINWAN 1g/kg, 2g/kg, 4g/kg, each dosage pastille serum+anoxia-induced apoptosis group of 8g/kg.
1.4.2.3 intervening measure
(1) blank group: add 10% blank group rat blood serum (DMEM/F12 culture fluid 90 μ l+ blank group rat blood serums 10 μ l) in the myocardial cell, place 37 ℃, 5%CO
2Hatch 24h in the incubator.(2) anoxia-induced apoptosis group: after adding 10% blank group rat blood serum (DMEM/F12 culture fluid 90 μ l+ blank group rat blood serums 10 μ l) in the myocardial cell, with cell place anaerobic environment (37 ℃, 94%N
2, 1%O
2, 5%CO
2) hatch 24h.(3) TONGMAIYANXINWAN 1g/kg, 2g/kg, 4g/kg, each dosage pastille serum+anoxia-induced apoptosis group of 8g/kg: add the 10% pastille serum (each dose groups pastille serum 10 μ l of DMEM/F12 culture fluid 90 μ l+ TONGMAIYANXINWAN) of each dose groups of TONGMAIYANXINWAN in the myocardial cell, all the other operate same anoxia-induced apoptosis group.
1.4.3ELISA method is measured the concentration of IL-6, IL-1 β
Get cell culture supernatant,, read light absorption value in the 450nm place on the ELIASA, calculate IL-6, IL-1 β concentration according to the operation of test kit description.
1.5 statistical procedures
Adopt SPSS 11.0 softwares to carry out statistical analysis; Measurement data adopts mean ± standard deviation
expression, relatively adopts one factor analysis of variance between group.
2 results
2.1 TONGMAIYANXINWAN pastille serum is to the influence of anoxia-induced apoptosis myocardial cell SOD, MDA, GSH
Table 1 shows, after the myocardial cell anoxia-induced apoptosis in the cell conditioned medium liquid SOD content obviously reduce (P＜0.01), MDA content obviously raise (P＜0.01); Each dose groups of TONGMAIYANXINWAN can improve in various degree SOD and GSH active, reduce MDA content, with anoxia-induced apoptosis group relatively there were significant differences (P＜0.05-0.01).
2.2 TONGMAIYANXINWAN pastille serum is to the influence of anoxia-induced apoptosis myocardial cell IL-6, IL-1 β concentration
Table 1 shows, after the myocardial cell anoxia-induced apoptosis in the cell conditioned medium liquid IL-1 β concentration raise (P＜0.05) IL-6 concentration significantly raise (P＜0.01); TONGMAIYANXINWAN 4g/kg dose groups pastille serum can reduce IL-6 concentration in the cell conditioned medium liquid (P＜0.05) and IL-1 β concentration (P＜0.01).
The influence
that table 1 TONGMAIYANXINWAN pastille serum discharges anoxia myocardial cell oxygen-derived free radicals
Annotate: compare with anoxia-induced apoptosis group
*P＜0.05,
*P＜0.01; Compare with the blank group
The Δ ΔP＜0.01.
Oxidative stress and inflammatory reaction are through the overall process of myocardial ischemia incidence and development.In the anoxia process, neutrophilic granulocyte combines with the myocardial cell adhesion molecule, discharge many have chemotaxis inflammatory mediator, a series of inflammatory reactions appear.Inflammatory mediator plays an important role in the process of myocardial cell anoxia-induced apoptosis.During myocardial ischemia, IL-1 β has participated in the overall process of myocardial damage through number of mechanisms: (1) promotes the apoptosis of ischemia-reperfusion cardiac muscle.(2) directly activate neutrophilic granulocyte.(3) ICAM-1, ELAM-1 cause myocardial cell injury through blocking mechanism such as blood capillary, release oxygen free radical, make the damage process aggravation.IL-6 is the crucial medium of chronic inflammatory disease, is called as the core member of interleukin family, has participated in the adjusting of inflammatory reaction.This paper expresses and studies with regard to anoxia-induced apoptosis myocardial cell model IL-1 β, IL-6, and the result shows that anoxia can cause the myocardial cell inflammatory factor to cross expression, has aggravated myocardial damage.Pharmaceutical composition of the present invention can suppress its expression, and the performance antiinflammatory action reaches the myocardium protecting action under the anoxia condition.
Under the anoxia condition; The generation system of free radical and the balance of free radical scavenging system are destroyed in the cell; Main scavenger enzyme superoxide dismutase (SOD), gst enzyme (GSH), catalase quantity such as (CAT) like interior free yl reduces, the active reduction; Thereby cause that intravital peroxide is on the increase, produce a large amount of unnecessary free radicals, cell membrane fluidity and permeability are changed.This paper investigates main oxygen free radical scavenger SOD, GSH and lipid within endothelial cells peroxide decomposition MDA, and experimental result shows, SOD in the myocardial cell supernatant after the anoxia-induced apoptosis, active significantly reduction of GSH and MDA content significantly increases; Pharmaceutical composition of the present invention has demonstrated the removing ability of oxygen-derived free radicals preferably, and the anoxia myocardial cell is had protective effect.
The specific embodiment
Followingly further describe for the present invention, its protection domain is not constituted and limit through the specific embodiment.
Embodiment 1
Step 1, take off the row medical material: Radix Rehmanniae 100g, Caulis Spatholobi 100g, Radix Ophiopogonis 60g, Radix Glycyrrhizae 60g, Radix Polygoni Multiflori Preparata 60g, Colla Corii Asini 60g, Fructus Schisandrae Chinensis 60g, Radix Codonopsis 60g, Carapax Et Plastrum Testudinis (vinegar system) 40g, Fructus Jujubae 40g, Ramulus Cinnamomi 20g;
Step 2, Caulis Spatholobi, Radix Codonopsis, Fructus Schisandrae Chinensis, Fructus Jujubae, Carapax Et Plastrum Testudinis decocte with water 2 times, each 3 hours, merging filtrate filtered, and is condensed into thick paste;
Step 3, all the other medical material 6 flavor medicine branches are broken into fine powder, add the thick paste that step 1 obtains, and evenly, drying divides to be broken into fine powder, sieves, and uses water pill, drying, and coating obtains pill.
Embodiment 2
Identical with the method for embodiment 1, except the composition of medical material different: Radix Rehmanniae 200g, Caulis Spatholobi 200g, Radix Ophiopogonis 138g, Radix Glycyrrhizae 138g, Radix Polygoni Multiflori Preparata 138g, Colla Corii Asini 138g, Fructus Schisandrae Chinensis 138g, Radix Codonopsis 138g, Carapax Et Plastrum Testudinis (vinegar system) 100g, Fructus Jujubae 100g, Ramulus Cinnamomi 40g.
Embodiment 3
Identical with the method for embodiment 1, except the composition of medical material different: Radix Rehmanniae 20g, Caulis Spatholobi 20g, Radix Ophiopogonis 20g, Radix Glycyrrhizae 20g, Radix Polygoni Multiflori Preparata 20g, Colla Corii Asini 20g, Fructus Schisandrae Chinensis 20g, Radix Codonopsis 20g, Carapax Et Plastrum Testudinis (vinegar system) 20g, Fructus Jujubae 20g, Ramulus Cinnamomi 10g.
Embodiment 4
Step 1, take off the row medical material: Radix Rehmanniae 100g, Caulis Spatholobi 100g, Radix Ophiopogonis 60g, Radix Glycyrrhizae 60g, Radix Polygoni Multiflori Preparata 60g, Colla Corii Asini 60g, Fructus Schisandrae Chinensis 60g, Radix Codonopsis 60g, Carapax Et Plastrum Testudinis (vinegar system) 40g, Fructus Jujubae 40g, Ramulus Cinnamomi 20g;
Step 2, get the Carapax Et Plastrum Testudinis decocte with water after 2 hours, add Caulis Spatholobi, Radix Codonopsis, Fructus Jujubae and continue to decoct 2 times, 4 hours for the first time, 2 hours for the second time; Filter, after filtrating is concentrated into relative density and is 1.05～1.15 (50 ℃), add 80% ethanol and precipitate to make and contain the alcohol amount and reach 60%, get an amount of; Add the Colla Corii Asini post-heating and make dissolving, incorporate in the above-mentioned alcoholic solution mixing into; Left standstill 24 hours, and filtered filtrate for later use;
Step 3, all the other 6 flavor medical materials added 80% alcohol dipping after 48 hours, and percolation is collected the extracting solution that obtains in percolate 1200ml and the step 2 and merged; Left standstill 24 hours, and filtered decompression filtrate recycling ethanol to relative density 1.01～1.05 (50 ℃); Add Mel 160g, benzoic acid 3g, adding water to total amount is 1000ml, mixing; Leave standstill, left standstill 7 days, filter and obtain product.
Embodiment 5
Identical with the method for embodiment 4, except the composition of medical material different: Radix Rehmanniae 200g, Caulis Spatholobi 200g, Radix Ophiopogonis 138g, Radix Glycyrrhizae 138g, Radix Polygoni Multiflori Preparata 138g, Colla Corii Asini 138g, Fructus Schisandrae Chinensis 138g, Radix Codonopsis 138g, Carapax Et Plastrum Testudinis (vinegar system) 100g, Fructus Jujubae 100g, Ramulus Cinnamomi 40g.
Embodiment 6
Identical with the method for embodiment 4, except the composition of medical material different: Radix Rehmanniae 20g, Caulis Spatholobi 20g, Radix Ophiopogonis 20g, Radix Glycyrrhizae 20g, Radix Polygoni Multiflori Preparata 20g, Colla Corii Asini 20g, Fructus Schisandrae Chinensis 20g, Radix Codonopsis 20g, Carapax Et Plastrum Testudinis (vinegar system) 20g, Fructus Jujubae 20g, Ramulus Cinnamomi 10g.
Claims (9)
1. the application of pharmaceutical composition in preparation anti-myocardial anoxia-induced apoptosis medicine, wherein said Chinese medicine composition is prepared from according to the Chinese medicine of following weight proportioning: 1～10 part of Radix Rehmanniae, 1～10 part of Caulis Spatholobi; 1～7 part of Radix Ophiopogonis, 1～7 part in Radix Glycyrrhizae, 1～7 part of Radix Polygoni Multiflori Preparata; 1～7 part in Colla Corii Asini, 1～7 part of Fructus Schisandrae Chinensis, 1～7 part of Radix Codonopsis; 1～5 part of Carapax Et Plastrum Testudinis, 1～5 part in Fructus Jujubae, 0.1～2 part of Ramulus Cinnamomi.
2. the described purposes of claim 1 is characterized in that said Chinese medicine composition is prepared from according to the Chinese medicine of following weight proportioning: 3～8 parts of Radix Rehmanniae, 3～8 parts of Caulis Spatholobis; 2～5 parts of Radix Ophiopogonis, 2～5 parts in Radix Glycyrrhizae, 2～5 parts of Radix Polygoni Multiflori Preparatas; 2～5 parts in Colla Corii Asini, 2～5 parts of Fructus Schisandrae Chinensis, 2～5 parts of Radix Codonopsis; 1～3 part of Carapax Et Plastrum Testudinis, 1～3 part in Fructus Jujubae, 0.5～1.5 part of Ramulus Cinnamomi.
3. the described purposes of claim 1 is characterized in that said Chinese medicine composition is prepared from according to the Chinese medicine of following weight proportioning: 5 parts of Radix Rehmanniae, 5 parts of Caulis Spatholobis, 3 parts of Radix Ophiopogonis; 3 parts in Radix Glycyrrhizae, 3 parts of Radix Polygoni Multiflori Preparatas, 3 parts in Colla Corii Asini, 3 parts of Fructus Schisandrae Chinensis; 3 parts of Radix Codonopsis, 2 parts of Carapax Et Plastrum Testudiniss, 2 parts in Fructus Jujubae, 1 part of Ramulus Cinnamomi.
4. the described purposes of claim 1 is characterized in that said Carapax Et Plastrum Testudinis is a Carapax et Plastrum Testudinis(processed with vinegar).
5. the described purposes of claim 1 is characterized in that the coronary heart disease that said anti-myocardial anoxia-induced apoptosis causes.
6. the described purposes of claim 1 is characterized in that said Chinese medicine composition Chinese medicine composition is prepared from according to following method, comprising:
Step 1, according to the said weight proportion of claim 1 get 11 the flavor medical materials;
Step 2, get the Carapax Et Plastrum Testudinis decocte with water after, add Caulis Spatholobi, Radix Codonopsis, Fructus Jujubae and continue to decoct, filter, after filtrating concentrates; Add ethanol and precipitate, get in right amount, add the Colla Corii Asini post-heating and make dissolving, incorporate in the above-mentioned alcoholic solution; Mixing leaves standstill, and filters filtrate for later use;
Step 3, all the other 6 flavor medical materials, after the adding alcohol dipping, percolation is collected the extracting solution that obtains in percolate and the step 2 and is merged, and leaves standstill, and filters, and decompression filtrate recycling ethanol obtains finished product.
7. the described purposes of claim 6 is characterized in that in step 2, and said Carapax Et Plastrum Testudinis decocte with water adds medical materials such as Caulis Spatholobi after 2 hours; Add medical material continued such as Caulis Spatholobi, Radix Codonopsis and Fructus Jujubae and decoct 2 times, 4 hours for the first time, 2 hours for the second time; It is 1.05～1.15 (50 ℃) that said filtrating is concentrated into relative density; Add 80% ethanol and precipitate, make ethanol content reach 60%; Left standstill 24 hours; In the step 3, the alcohol dipping of employing 80% 48 hours; Left standstill 24 hours.
8. the described purposes of claim 1 is characterized in that said Chinese medicine composition Chinese medicine composition is prepared from according to following method, comprising:
Step 1, according to the said weight proportion of claim 1 get 11 the flavor medical materials;
Step 2, Caulis Spatholobi, Radix Codonopsis, Fructus Schisandrae Chinensis, Fructus Jujubae, Carapax Et Plastrum Testudinis decocte with water, merging filtrate filters, and is condensed into thick paste;
Step 3, all the other medical material 6 flavor medicine branches are broken into fine powder, add the thick paste that step 1 obtains, and evenly, drying divides to be broken into fine powder, obtains finished product.
9. the described purposes of claim 8 is characterized in that in the step 2, and medical material decocts 2 times, each 3 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105815388A CN102526461A (en) | 2010-12-09 | 2010-12-09 | Application of traditional Chinese medicine composition in preparing medicament for resisting myocardial cell hypoxic injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105815388A CN102526461A (en) | 2010-12-09 | 2010-12-09 | Application of traditional Chinese medicine composition in preparing medicament for resisting myocardial cell hypoxic injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102526461A true CN102526461A (en) | 2012-07-04 |
Family
ID=46335281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105815388A Pending CN102526461A (en) | 2010-12-09 | 2010-12-09 | Application of traditional Chinese medicine composition in preparing medicament for resisting myocardial cell hypoxic injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526461A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104777247A (en) * | 2015-04-02 | 2015-07-15 | 天津中新药业集团股份有限公司乐仁堂制药厂 | Method for determining active ingredients with myocardial protection and anti-inflammatory action in traditional Chinese medicine |
| CN115607622A (en) * | 2022-11-07 | 2023-01-17 | 津药达仁堂集团股份有限公司乐仁堂制药厂 | Application of traditional Chinese medicine composition in preparation of medicine for improving microcirculation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396519A (en) * | 2007-09-28 | 2009-04-01 | 天津中新药业集团股份有限公司乐仁堂制药厂 | Quality control method of pulse-invigorating and heart-nourishing pill |
-
2010
- 2010-12-09 CN CN2010105815388A patent/CN102526461A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396519A (en) * | 2007-09-28 | 2009-04-01 | 天津中新药业集团股份有限公司乐仁堂制药厂 | Quality control method of pulse-invigorating and heart-nourishing pill |
Non-Patent Citations (2)
| Title |
|---|
| 国家药典委员会: "《中华人民共和国药典》", 31 January 2010, article "通脉养心口服液" * |
| 韩德承: "通脉养心丸", 《医药养生保健报》, 7 April 2008 (2008-04-07) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104777247A (en) * | 2015-04-02 | 2015-07-15 | 天津中新药业集团股份有限公司乐仁堂制药厂 | Method for determining active ingredients with myocardial protection and anti-inflammatory action in traditional Chinese medicine |
| CN104777247B (en) * | 2015-04-02 | 2016-08-31 | 天津中新药业集团股份有限公司乐仁堂制药厂 | The method determining the active component in Chinese medicine with myocardial preservation and antiinflammatory action |
| CN115607622A (en) * | 2022-11-07 | 2023-01-17 | 津药达仁堂集团股份有限公司乐仁堂制药厂 | Application of traditional Chinese medicine composition in preparation of medicine for improving microcirculation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104826087A (en) | Composite moringa polypeptide and preparation method and application thereof | |
| CN101292742A (en) | Health food for reinforcing immune function of human body and preparation technique thereof | |
| CN103740566B (en) | Rosa roxbunghii medicinal liquor and preparation method thereof | |
| CN103734696B (en) | A kind of soft capsule and preparation method thereof improving immunity, protection internal organs | |
| CN102293802B (en) | Medicinal composition for treating cardiovascular diseases and preparation method thereof | |
| CN100556429C (en) | A kind of pharmaceutical composition that contains Fructus Vitis viniferae extract and preparation method thereof, purposes | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| KR20110128384A (en) | The composition material and the manufacturing process for skin-wrinkle, moisture and skin-lightening uses by midam-kyungokko | |
| KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
| CN102526461A (en) | Application of traditional Chinese medicine composition in preparing medicament for resisting myocardial cell hypoxic injury | |
| CN101020016B (en) | Medicine for treating fracture and injured tendon and its preparation | |
| CN109628265A (en) | A kind of liver-protection health-care molecule wine and preparation method thereof containing general flavone | |
| CN113144014B (en) | Compound pharmaceutical composition and application thereof | |
| KR20140080289A (en) | Composition for preventing or treating of oxidative brain injury and brain function disorder | |
| CN110772456B (en) | Miracle fruit leaf compound and application thereof in anti-melanin formation product | |
| CN1332688C (en) | Medication for treating dementia in blood vessel type, and preparation method | |
| CN106728962B (en) | Pharmaceutical composition for enhancing immunity and application thereof | |
| CN102357151A (en) | Chinese medicinal composition for delaying senility and preparation process thereof | |
| CN112336764A (en) | Traditional Chinese medicine composition for resisting oxidation and enhancing immunity and preparation method and application thereof | |
| CN112843172A (en) | Chinese and western medicinal composition for improving human body function and discharging harmful toxin, and its preparation method | |
| CN105125898A (en) | Medicinal preparation containing milkvetch roots and gastrodia elata and having function of tonifying qi and nourishing blood | |
| CN102430001A (en) | Compound rose-hip flavone preparation for preventing diabetes mellitus and preparation method thereof | |
| CN104277955A (en) | Traditional Chinese medicine wine for tonifying qi, nourishing blood and preserving health and preparation method thereof | |
| CN111000237A (en) | Dietary composition for dietary intervention of cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1679912B (en) | Extraction of liuwei Dihuang polysaccharide, products and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120704 |